Blocking the B7-H4 Pathway with Novel Recombinant Antibodies Enhances T Cell-Mediated Antitumor Responses

Citation

Dangaj, D., & Scholler, N. (2013). Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses. Oncoimmunology, 2(8), e25913.

Abstract

B7-H4 inhibits T-cell activation and is widely expressed by solid neoplasms. We have recently demonstrated that the expression of B7-H4 on the surface of malignant cells in vivo is inducible, and that novel anti-B7-H4 recombinant antibodies can reverse the inhibition of tumor-specific T cells. Thus, antibodies targeting the B7-H4 pathways may extend the survival of cancer patients by restoring T cell-mediated antitumor responses.


Read more from SRI

  • Banner and attendees at the IEEE Hard Tech Venture Summit

    Cultivating hard tech startups that scale

    IEEE’s Hard Tech Venture Summit convened innovators at SRI to refine strategies and build new networks.

  • Patient going into a MRI

    Bringing surgical tools inside the MRI

    Drawing on SRI’s unique innovation ecosystem, the startup Medical Devices Corner is seeking to improve cancer surgery by advancing MRI-safe teleoperation.

  • Christopher Mims and Susan Patrick

    PARC Forum: How to AI

    The Wall Street Journal tech columnist Christopher Mims and SRI Education’s Susan Patrick discuss how AI can strengthen human agency.